Drug Profile
FT 516
Alternative Names: FT516; FT516i; hnCD16 engineered iPSC-derived NK cell therapyLatest Information Update: 10 Nov 2023
Price :
$50
*
At a glance
- Originator University of Minnesota
- Developer Fate Therapeutics; Masonic Cancer Center; University of Minnesota
- Class Antineoplastics; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies; Natural killer cell therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; B-cell lymphoma; COVID 2019 infections; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Most Recent Events
- 23 Oct 2023 Fate Therapeutics terminates a phase I trial in Acute myeloid leukaemia (Second-line therapy or greater) and B-cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT04023071)
- 21 Sep 2023 Fate Therapeutics terminates a phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) due to the sponsor decison (NCT04551885)
- 05 Jan 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA (Parenteral)